John Babich
Seminars
Wednesday 2nd December 2026
Panel Discussion: Why Are Big Pharma Betting on Targeted Radiopharmaceuticals?
5:00 pm
- Exploring the scientific, clinical and commercial factors driving increasing investment into targeted radiopharmaceuticals from large pharmaceutical companies
- Comparing the evolution of the radiopharmaceutical landscape with the rapid growth of antibody-drug conjugates and identifying the key lessons that can be applied across modalities
- Debating whether radiopharmraceuticals are approaching a similar inflection point to ADCs and what challenges still need to be overcome to unlock broader adoption
Tuesday 1st December 2026
Engineering the Next Generation of Radiopharmaceutical Platforms: Lessons Learned from First-Generation RLTs
11:00 am
- Understanding the pharmacokinetic limitations restricting today’s radioligand therapies
- Optimising vector design, tumour localisation and therapeutic index to improve clinical outcomes
- Applying platform-level lessons to develop more effective next generation radiopharmaceuticals
